Reuters logo
8 months ago
BRIEF-Akebia Therapeutics entered into collaboration, license agreement with Otsuka Pharmaceutical on Dec. 18
December 20, 2016 / 12:34 PM / 8 months ago

BRIEF-Akebia Therapeutics entered into collaboration, license agreement with Otsuka Pharmaceutical on Dec. 18

Dec 20 (Reuters) - Akebia Therapeutics Inc :

* Akebia Therapeutics Inc - on December 18, 2016, co entered into collaboration and license agreement with Otsuka pharmaceutical co - sec filing

* Akebia Therapeutics Inc - under terms of agreement, otsuka will pay Akebia an upfront payment of $125 million

* Akebia therapeutics inc - agreement also provides for additional funding for global development program for Vadadustat, totaling $105 million or more

* Akebia Therapeutics Inc - unless earlier terminated, agreement will expire when a generic version of vadadustat achieves 90% market penetration

* Akebia - Otsuka will reimburse co about $35 million for expenses previously incurred by Akebia for its ongoing global development program for vadadustat

* Akebia Therapeutics Inc - Akebia agreed to co-exclusively collaborate with Otsuka to development, commercialization in U.S. Of Vadadustat

* Akebia Therapeutics- Akebia is eligible to receive from Otsuka up to $765 million in specified development and commercial milestones of Vadadustat Source text (bit.ly/2gXjKRs) Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below